PARTNERSHIP AND EXHIBITION PROSPECTUS
At Iridex, we are redefining the glaucoma treatment paradigm with a versatile range of non-incisional, laser-based therapies: MicroPulse Laser Trabeculoplasty, MicroPulse Transscleral Laser Therapy, and Continuous-Wave Transscleral Cyclophotocoagulation. These therapies
provide physicians safe, effective, and versatile treatment options for a wide variety of glaucoma types and severities, to significantly reduce intraocular pressure and slow the progression of vision loss. More than 200,000 patients have been treated since 2015 with MicroPulse® TLT using the MicroPulse P3® Delivery Device. Visit iridex.com/webinars to learn how ophthalmologists and patients benefit from our non-incisional glaucoma procedures.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. For more information, go to www.bayer.com.
DKSH is the leading growth partner for pharmaceutical companies in Asia. Our experts provide a range of integrated Market Expansion Services across the entire value chain, ranging from registration through to marketing, promotion and distribution.
Our capillary network reaches more than 130,000 hospitals, clinics, pharmacies, doctors and drugstores in Asia. Products are transported, stored and distributed efficiently thanks to our unmatched capacities and expertise in the region. Our solid infrastructure and dedication to compliance and quality reduce business risks for our partners.
We are committed to delivering the results you need to be successful. That’s why we continuously invest in our sales and marketing organization, which is fully embedded in our operations. Our teams work with clear measurements, activity-driven KPIs and standardized brand planning processes across the region. They are supported by regional Sales and Marketing Excellence and Business Development teams, allowing us to duplicate success across markets.
Headquartered and publicly listed in Switzerland, our local experts provide services to pharmaceutical companies in 13 Asian markets.
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
We were the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure that revolutionized the treatment and management of glaucoma. In 2012, we launched our first MIGS device—the iStent®—in the United States, followed by our next-generation iStent inject® device in September 2018 and iStent inject® W in September 2020.
In November 2019, Glaukos acquired Avedro, maker of the first and only FDA-approved cross-linking technology for progressive keratoconus. And we continue to seek to leverage our platform technologies to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies for
glaucoma, corneal health, and retinal diseases.
Our company completed an initial public offering in June of 2015, and our shares are traded on the New York Stock Exchange under the ticker symbol “GKOS”. Our global headquarters is located in Aliso Viejo, California, and we have additional locations in 9 regions around the world.